If you look at this image, of they 17 mestastatic, only 1 had no Ccr5, very small percentage, but it is possible. There is some MOAs cancer could use that leronlimab will not help against. I suspect some it helps initiatly could switch to those MOAs, how large and how long, I don’t know, but that initial percentage 16/17 possibility through Ccr5 looks very promising.